[1] Lopez-Pousa A, Martin BJ, Garrido T, Vazquez J. Giant cell tumour of bone: new treatments in development. Clin Transl Oncol. 2015;17:419-30.
[2] Verschoor AJ, Bovee J, Mastboom M, Sander DP, Van De Sande M, Gelderblom H. Incidence and demographics of giant cell tumor of bone in The Netherlands: First nationwide Pathology Registry Study. Acta Orthop. 2018;89:570-4.
[3] Errani C, Ruggieri P, Asenzio MA, Toscano A, Colangeli S, Rimondi E, et al. Giant cell tumor of the extremity: A review of 349 cases from a single institution. Cancer Treat Rev. 2010;36:1-7.
[4] Zou C, Lin T, Wang B, Zhao Z, Li B, Xie X, et al. Managements of giant cell tumor within the distal radius: A retrospective study of 58 cases from a single center. J Bone Oncol. 2019;14:100211.
[5] van der Heijden L, Dijkstra PD, Campanacci DA, Gibbons CL, van de Sande MA. Giant cell tumor with pathologic fracture: should we curette or resect? Clin Orthop Relat Res. 2013;471:820-9.
[6] Present D, Bertoni F, Hudson T, Enneking WF. The correlation between the radiologic staging studies and histopathologic findings in aggressive stage 3 giant cell tumor of bone. Cancer-Am Cancer Soc. 1986;57:237-44.
[7] Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GJ. Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics. 2013;33:197-211.
[8] Palmerini E, Picci P, Reichardt P, Downey G. Malignancy in Giant Cell Tumor of Bone: A Review of the Literature. Technol Cancer Res Treat. 2019;18:1078107648.
[9] Gong L, Liu W, Sun X, Sajdik C, Tian X, Niu X, et al. Histological and clinical characteristics of malignant giant cell tumor of bone. Virchows Arch. 2012;460:327-34.
[10] Itkin B, Straminsky S, De Ronato G, Lewi D, Marantz A, Bardach A. Prognosis of metastatic giant cell tumor of bone in the pre-denosumab era. A systematic review and a meta-analysis. Jpn J Clin Oncol. 2018;48:640-52.
[11] Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the Surveillance, Epidemiology and End Results Program (1975-2004). Rare Tumors. 2009;1:e52.
[12] Jr FEH. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. 2010:2-26.
[13] Domovitov SV, Healey JH. Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol. 2010;17:694-701.
[14] Junior RC, Pereira MG, Garcia PB, Santos PA, Cavalcanti AS, Meohas W. Epidemiological study on giant cell tumor recurrence at the Brazilian National Institute of Traumatology and Orthopedics. Rev Bras Ortop. 2016;51:459-65.
[15] Niu X, Zhang Q, Hao L, Ding Y, Li Y, Xu H, et al. Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am. 2012;94:461-7.
[16] Jiang N, Qin CH, Tan CX, Wen SF, Ma YF, Dong F, et al. A retrospective analysis of 140 patients with giant cell tumor in the extremity: a multicenter study based on four hospitals in South China. Cancer Epidemiol. 2013;37:294-9.
[17] Rosario M, Kim HS, Yun JY, Han I. Surveillance for lung metastasis from giant cell tumor of bone. J Surg Oncol. 2017;116:907-13.
[18] Dominkus M, Ruggieri P, Bertoni F, Briccoli A, Picci P, Rocca M, et al. Histologically verified lung metastases in benign giant cell tumours--14 cases from a single institution. Int Orthop. 2006;30:499-504.
[19] Wang B, Chen W, Xie X, Tu J, Huang G, Zou C, et al. Development and validation of a prognostic index to predict pulmonary metastasis of giant cell tumor of bone. Oncotarget. 2017;8:108054-63.
[20] Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, et al. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. World J Surg Oncol. 2018;16:160.
[21] Cheng DD, Hu T, Zhang HZ, Huang J, Yang QC. Factors Affecting the Recurrence of Giant Cell Tumor of Bone After Surgery: A Clinicopathological Study of 80 Cases from a Single Center. Cell Physiol Biochem. 2015;36:1961-70.
[22] Yang Y, Huang Z, Niu X, Xu H, Li Y, Liu W. Clinical characteristics and risk factors analysis of lung metastasis of benign giant cell tumor of bone. J Bone Oncol. 2017;7:23-8.
[23] Kito M, Matusmoto S, Ae K, Tanizawa T, Gokita T, Kobayashi H, et al. Pulmonary metastasis from giant cell tumor of bone: clinical outcome prior to the introduction of molecular target therapy. Jpn J Clin Oncol. 2017;47:529-34.
[24] Pazionis TJ, Alradwan H, Deheshi BM, Turcotte R, Farrokhyar F, Ghert M. A Systematic Review and Meta-Analysis of En-Bloc vs Intralesional Resection for Giant Cell Tumor of Bone of the Distal Radius. Open Orthop J. 2013;7:103-8.
[25] Zhang S, Zhang J, Wang X. Comparison of tumor curettage and resection for treatment of giant cell tumor of the bone around the knee joint. Pak J Med Sci. 2016;32:662-6.
[26] Charest-Morin R, Fisher CG, Varga PP, Gokaslan ZL, Rhines LD, Reynolds JJ, et al. En Bloc Resection Versus Intralesional Surgery in the Treatment of Giant Cell Tumor of the Spine. Spine (Phila Pa 1976). 2017;42:1383-90.
[27] Guo X, Zhang C, Ma W, Tian F, Xu G, Han X, et al. Patterns of bone metastases in newly diagnosed colorectal cancer: a real-world analysis in the SEER database. Int J Colorectal Dis. 2019.
[28] Zhang C, Guo X, Peltzer K, Ma W, Qi L, Zhang Y, et al. The prevalence, associated factors for bone metastases development and prognosis in newly diagnosed ovarian cancer: a large population based real-world study. J Cancer. 2019;10:3133-9.